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SUMMARY
The generation of induced pluripotent stem cells (iPSCs) from differentiated cells following forced expression of OCT4, KLF4, SOX2, and
C-MYC (OKSM) is slow and inefficient, suggesting that transcription factors have to overcome somatic barriers that resist cell fate change.
Here, we performed an unbiased serial shRNA enrichment screen to identify potent repressors of somatic cell reprogramming into iPSCs.
This effort uncovered the protein modifier SUMO2 as one of the strongest roadblocks to iPSC formation. Depletion of SUMO2 both en-
hances and accelerates reprogramming, yielding transgene-independent, chimera-competent iPSCs after as little as 38 hr of OKSM
expression. We further show that the SUMO2 pathway acts independently of exogenous C-MYC expression and in parallel with
small-molecule enhancers of reprogramming. Importantly, suppression of SUMO2 also promotes the generation of human iPSCs.
Together, our results reveal sumoylation as a crucial post-transcriptional mechanism that resists the acquisition of pluripotency from
fibroblasts using defined factors.
INTRODUCTION
The reprogramming of somatic cells into pluripotent cells
using the classical set of transcription factors, OCT4,
KLF4, SOX2, andC-MYC (OKSM) and conventional culture
conditions (leukemia inhibitory factor, serum) usually
takes several weeks and yields induced pluripotent stem
cells (iPSCs) at extremely low frequencies (0.1%–3%) (Taka-
hashi and Yamanaka, 2006). This observation suggests that
reprogramming factors need to overcome undefined bar-
riers that have been established by somatic cells to preserve
cell identity and resist cell fate change. Identifying road-
blocks to iPSC generation thus provides a valuable platform
to dissect general principles of cell identity and cell fate
change (Apostolou and Hochedlinger, 2013).
Previously identified barriers to reprogramming include
regulators of cell cycle progression and senescence (e.g.,
P53, INK4A/ARF) (Krizhanovsky and Lowe, 2009), histone
and DNA modifications (e.g., DNMT1, KDM2B, MBD3)
(Mikkelsen et al., 2008; Rais et al., 2013; Wang et al.,
2011), as well as signaling pathways and epigenetic pro-
cesses that can be targeted by small compounds (e.g., ascor-
bic acid, GSK3 inhibitor, DOT1L inhibitor) (Bar-Nur et al.,
2014; Esteban et al., 2010; Onder et al., 2012; Silva et al.,
2008). However, suppression of some of these barriers may
enhance iPSC formation only under specific culture condi-
tions (e.g., MBD3) (dos Santos et al., 2014; Rais et al.,
2013), potentially limiting its usefulness in different cellular
contexts. Moreover, manipulation of certain barriers causes
permanent aberrations of the epigenome (e.g., DNMT1)
(Jackson-Grusby et al., 2001), complicating its applications
in a therapeutic setting.
More recently, unbiased small hairpin RNA (shRNA)
screenshavebeenperformedduring iPSCformation, leading
to the identification of novel roadblocks to reprogramming
(Qin et al., 2014; Samavarchi-Tehrani et al., 2010; Yang
et al., 2014). Surprisingly, individual suppression of hits
that emerged from these screens showed rather modest
effects (2- to 4-fold enhancement) compared with the
simultaneous suppression of multiple hits (5- to 10-fold
enhancement). Furthermore, there was little overlap among
independent screening efforts, suggesting that reprogram-
ming may be restrained by additional, yet to be identified
barriers. Indeed, our lab recently discovered the histone
chaperone CAF-1 as a novel barrier to iPSC generation using
a chromatin-focused shRNA screen (Cheloufi et al., 2015).
The goal of this study was to identify potent roadblocks
to reprogramming by performing a serial genome-wide
shRNA enrichment screen in combination with a well-
defined transgenic reprogramming system. Our screening
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Figure 1. A Genome-Wide Serial shRNA Enrichment Screen during iPSC Generation
(A) Fluorescencemicroscopy image of a primary iPSC colony showing lentiviral tRFP (shRNA) expression andendogenousOct4-GFP expression.
(B) Gating strategy to purify Oct4-GFP+ cells from lentivirally transduced cultures undergoing reprogramming.
(C) Schematic representation of one reprogramming/shRNA enrichment cycle.
(D) Overview of serial enrichment screen and validation experiments.
(E) Timeline of reprogramming experiments and strategy to collect control and experimental samples for subsequent analysis of shRNA
library representation.
(F) Change in shRNA library complexity during enrichment screen, i.e., number of unique shRNAs at the start of rounds 1–5.
(legend continued on next page)
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strategy uncovered SUMO2 as a top-scoring hit, thus impli-
cating protein sumoylation as amechanism that effectively
resists transcription factor-induced pluripotency.
RESULTS
Serial shRNA Screen for Roadblocks to
Reprogramming
To identify roadblocks to iPSC formation in an unbiased
manner, we combined awell-defined transgenic reprogram-
ming system with a genome-wide shRNA library targeting
18,464 genes with 60,642 hairpins. We utilized murine em-
bryonic fibroblasts (MEFs) carrying a doxycycline (dox)-
inducible polycistronic cassette encompassing the open
reading frames for Oct4, Klf4, Sox2, and c-Myc (OKSM) in
the Col1a1 locus, the M2-rtTA transactivator in the Rosa26
locus, and an EGFP reporter in the endogenous Pou5f1
(Oct4) locus (Stadtfeld et al., 2010). We will refer to these
transgenic MEFs as ‘‘reprogrammable cells’’ and the geno-
type as ‘‘Col1a1-tetOP-OKSM; R26-M2rtTA; Oct4-GFP.’’ The
shRNA library was generated by cloning shRNAs into the
pHAGE-Mir lentiviral vector carryingapuromycin resistance
gene and a turbo red fluorescent protein (tRFP) reporter
(Meerbrey et al., 2011; Schlabach et al., 2008) (see Experi-
mental Procedures for details). Transduction of reprogram-
mable MEFs with an identical empty vector gave rise to
Oct4-GFP+, tRFP+ iPSCcolonies uponexposure todox, albeit
at slightly lower frequencies than uninfected cells (Figures
1A and 1B; data not shown), demonstrating the feasibility
of an shRNA screen using these cells and vector system.
To identify shRNAs that strongly enhance reprogram-
ming with low background signal from passenger shRNAs,
we devised a pooled screening strategy using serial enrich-
ment of hairpin libraries. In brief, we infected reprogram-
mable MEFs with the pooled shRNA library 2 days before
dox induction to ensure effective suppression of targets
prior to initiation of reprogramming. After 10 days of
OKSM expression, dox was withdrawn for 4 days to select
for stably reprogrammed, transgene-independent colonies,
followed by purification of emerging Oct4-GFP+ cells by
flow cytometry (Figure 1C). Enriched hairpins were ampli-
fied by PCR from genomic DNA and subsequently recloned
into the original viral backbone before initiating another
round of viral transduction and reprogramming. We per-
formed five rounds of reprogramming and shRNA enrich-
ment before focusing on candidates (Figures 1D and 1E).
Parallel cultures of reprogrammable MEFs were exposed
to dox alone or transduced with the viral library in the
absence of dox before extracting genomic DNA (Figures
1E and S1); these samples served as controls for possible
passenger hairpins that became passively enriched in ex-
panding iPSC colonies or hairpins that merely affected
the growth of uninduced reprogrammable MEFs. Library
representation was then determined in all samples by
deep (Illumina) sequencing of genomic DNA. Notably, we
detected a gradual reduction of library complexity and a
progressive accumulation of specific shRNA vectors during
the five rounds of screening, suggesting enrichment of bio-
logically meaningful hairpins (Figures 1F and 1G).
SUMO2 Emerges as a Top-Scoring Candidate Barrier to
Reprogramming
We next applied stringent criteria to call hits based on
the number of normalized reads and the cumulative fold
change of shRNAs across all rounds of reprogramming
relative to controls (Figure S1). Analysis of shRNAs that
were consistently enriched revealed several candidate bar-
riers to reprogramming including FGF5, SMPDL3A, and
SUMO2 (Figures 1F–1H). Of note, some of the top-scoring
shRNAs affected pathways that were previously shown to
block reprogramming, including members of the FGF/
FGFR and OLFR families (Dejosez et al., 2013; Qin et al.,
2014). A complete list of candidates with associated cumu-
lative enrichment scores is shown in Table S1. Of the 27
validated shRNAs, seven showed a more than 2-fold in-
crease in iPSC formation (Gstt4, Gm719, Sqrdl, Dnmt3a,
BTBD10, Smpdl3a, Sumo2) (Figure 1H), with Sumo2 shRNA
exhibiting the strongest phenotype.
Given the prominent effects on reprogramming of
shRNAs targeting Sumo2, we will focus on this gene for
the remainder of this article. SUMO2 (small ubiquitin-like
modifier 2) is a ubiquitin-related protein that can be cova-
lently attached to proteins as a lysine-linked monomer or
polymer. This post-translational modification, lysine su-
moylation, controls the stability, activity, and localization
of hundreds of proteins and has been implicated in a num-
ber of biological processes including DNA replication and
repair, heterochromatic gene silencing, and signal trans-
duction (Flotho and Melchior, 2013).
Suppression of SUMO2 Promotes Reprogramming
without Compromising Proliferation or Pluripotency
Using more quantitative reprogramming assays, we found
that suppression of SUMO2 increases the number of trans-
gene-independent alkaline phosphatase-positive (AP+)
(G) Heatmap depicting fold-change enrichment of shRNAs during five rounds of reprogramming. Blue bars represent lost shRNAs whereas
red bars represent enriched shRNA relative to controls (see Experimental Procedures for details).
(H) Validation of candidates identified in serial shRNA screen (mean value from three biological replicates ± SD). Red bars depict shRNAs
yielding a 2-fold or higher increase in reprogramming efficiency.
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Figure 2. Suppression of SUMO2 Robustly Enhances and Accelerates Reprogramming
(A) Flow cytometric analysis of Oct4-GFP expression in reprogrammable MEFs after 8 days of OKSM expression in the presence of indicated
shRNAs.
(B) Quantification of data shown in (A); shown is percentage of Oct4-GFP+ cells per total number of cells using three biological replicates
(mean ± SD).
(C) Alkaline phosphatase (AP) staining of iPSC colonies derived from reprogrammable MEFs transfected with indicated siRNAs.
(D) Quantification of data shown in (C); data represent mean from three biological replicates ± SD.
(E) Western blot analysis for SUMO2 expression in reprogrammable MEFs infected with indicated shRNA vectors and treated with doxy-
cycline (dox) for 3 days.
(F) Expression dynamics of Sumo2mRNA in MEFs, iPSCs, and intermediate stages of reprogramming using a previously published expression
time course (Polo et al., 2012). Thy1, fibroblast marker; Nanog, pluripotency marker.
(G) Scheme to determine minimal duration of OKSM expression (in days) required to achieve transgene-independent iPSC colonies.
(H) Data obtained from experiments depicted in (G) using indicated shRNAs and three biological replicates (mean ± SD).
(legend continued on next page)
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iPSC-like colonies and the fraction of Oct4-GFP+ cells by 7-
to 8-fold (16%Oct4-GFP+ cells with Sumo2 shRNA; 2%with
control shRNA at day 8) (Figures 2A–2D). We were able to
recapitulate enhanced reprogramming with six indepen-
dent shRNAs as well as small interfering RNA (siRNA) pools
targeting Sumo2, documenting the consistency of the
observed phenotype using either permanent or transient
knockdown approaches (Figures 2C, 2D, and S2A). Expres-
sion of Sumo2 shRNAs led to reduced Sumo2 transcript
levels as well as a decrease of free and conjugated SUMO2
protein levels, demonstrating specificity of the knockdown
vector and diminution of global sumoylation levels (Fig-
ures 2E and S2B). Considering that sumoylated KLF4
reportedly inhibits cellular reprogramming (Tahmasebi
et al., 2013), we next determined whether SUMO2 suppres-
sion leads to reducedKLF4 sumoylation.However,we failed
to detect obvious differences in KLF4’s sumoylation status
in cells expressing OKSM and Sumo2 shRNAs in a prelimi-
nary experiment, suggesting that the effect of SUMO2 on
iPSC formation may involve other targets (Figure S2C).
Moreover, forced expression of SUMO2 during iPSC gener-
ation (Figure S2D) was insufficient to block reprogramming
(data not shown), indicating that downregulation of
SUMO2maynot be required to attain pluripotency. Indeed,
we found that endogenous Sumo2mRNA levels were com-
parable betweenMEFs and iPSCsandbarely changedduring
the reprogramming process (Figure 2F). These results sug-
gest that SUMO2 may play independent roles in somatic
and pluripotent cell types. iPSCs generated with Sumo2
shRNAs could be stably propagated over many passages
and gave rise to well-differentiated teratomas, demon-
strating that suppression of SUMO2 does not compromise
the self-renewal or pluripotency of iPSCs (Figure S3A).
To complement the aforementionedmarker-based assays
of reprogramming with a functional readout, we deter-
mined whether suppression of SUMO2 could promote
the formation of transgene-independent iPSC colonies af-
ter reduced pulses of OKSM expression (Figure 2G). Indeed,
we found that knockdown of SUMO2 yielded transgene-
independent iPSC colonies after only 4–5 days of OKSM
expression, whereas stable iPSC colonies only emerged be-
tween days 6 and 8 in controls, consistent with previous
findings (Stadtfeld et al., 2008) (Figure 2H). In agreement
with this observation, we detected a significant upregula-
tion of key embryonic stem cell (ESC)-associated tran-
scripts (e.g., Nanog, Nr5a2, Sall4) and epigenetic regulators
(e.g.,Dnmt3b and Tet1) as well as a downregulation ofMEF-
associated transcripts (e.g., Twist2, Fgf18, Meox2) in cells
expressing OKSM and Sumo2 shRNAs at day 6 of reprog-
ramming relative to a non-targeting shRNA control (Fig-
ures 2I and 2J). Critically, knockdown of SUMO2 had no
discernible effect on cell proliferation or apoptosis of bulk
cultures, thus excluding the possibility that the observed
phenotype is due to accelerated growth or reduced cell
death (Figures S3B and S3C). Together, these results
demonstrate that both transient and constitutive suppres-
sion of SUMO2markedly enhances and accelerates the for-
mation of iPSCs from somatic cells.
SUMO2 Suppression Acts during Early-to-Mid Stages
of Reprogramming
To understand how SUMO2 suppression influences the dy-
namics of iPSC formation, we utilized surfacemarkers and a
reporter allele to distinguish between early, mid, and late
stages of reprogramming. We previously showed that cells
undergoing successful reprogramming initially upregulate
SSEA1 (early stage), followed by sequential activation of
EPCAM (mid stage) and Oct4-GFP (late stage) (Polo et al.,
2012; Stadtfeld et al., 2008) (Figure 3A). SUMO2 depletion
had no pronounced effect on the earliest intermediates of
reprogramming, as shown by comparable fractions of
SSEA1+ and EPCAM+ cells at day 3 relative to controls (Fig-
ures 3B, 3C, and S4). However, we noticed a 3-fold increase
in the fraction of SSEA1+ cells and a 5-fold increase in the
fraction of EPCAM+ cells by day 5 as well as an 8-fold
increase in the fraction of Oct4-GFP+ cells by day 8 of re-
programming. These data indicate that SUMO2 suppres-
sion facilitates early-to-mid stages of iPSC formation based
on surface marker expression in bulk cultures.
To corroborate the notion that SUMO2 suppression pro-
motes early-to-mid stages of reprogramming, we deter-
mined iPSC colony formation efficiencies after transfecting
reprogrammable MEFs with siRNAs against Sumo2 either
once (on day 0) or twice (on days 0 and 3) (Figures 3D
and 3E). iPSC colony formation was essentially the same
when SUMO2was suppressed initially or continuously dur-
ing a 6-day reprogramming period, suggesting that early
SUMO2 suppression is sufficient to elicit enhanced reprog-
ramming. Consistent with the acceleration of reprogram-
ming upon suppression of SUMO2, we find that MEFs
expressing OKSM and Sumo2 shRNAs for only 6 days are
molecularly most similar to advanced stages of reprogram-
ming (day 9 and day 12 intermediates) using a previous
expression time course (Polo et al., 2012), whereasMEFs ex-
pressing OKSM and a control shRNA are most similar to
day-6 intermediates, as expected (Figure 3F).
(I) Scatterplot comparing microarray data (log2 values) of day-6 reprogramming intermediates expressing indicated shRNAs. Represen-
tative upregulated pluripotency genes are shown in red whereas downregulated somatic genes are shown in green.
(J) Normalized expression levels of representative pluripotency-associated and MEF-associated genes in indicated samples at day 6 of
OKSM expression. Data obtained from one experiment. RepMEFs, reprogrammable MEFs; ESCs, embryonic stem cells.
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Collectively these phenotypic, functional, and molecu-
lar data suggest that SUMO2 suppression accelerates
early-to-mid stages of reprogramming, ultimately leading
to a strong increase in the number of Oct4+ transgene-inde-
pendent iPSCs.
SUMO2 Suppression Acts Independently of C-MYC
and in Parallel with Small Molecules
We next investigated whether exogenous C-MYC expres-
sion is required for the enhancement of iPSC formation
by Sumo2 shRNAs. To this end, we derived reprogrammable
MEFs from mice carrying the Col1a1-tetOP-OKS-mCherry
allele (lacking the c-Myc transgene) in combination with
the R26-M2rtTA allele (Figure 4A). Exposure of these MEFs
to dox alone gave rise to extremely few, if any, AP+ colonies
after 9–21 days of OKS expression, and no Oct4-GFP+ cells
could be detected by day 9 of reprogramming (Figures 4B–
4D). By contrast, depletion of SUMO2 in these cells using
transient transfection of siRNA pools yielded iPSC colonies
and stable Oct4-GFP+ cells by flow cytometry as early as
9 days after OKS induction. We conclude that suppression
of SUMO2 enhances reprogramming independently of
exogenous C-MYC expression, thus enabling iPSC forma-
tion in the absence of this potent oncogene.
To determine whether SUMO2 suppression acts in paral-
lel with small molecules that were previously shown
to enhance reprogramming, we treated reprogrammable
cells harboring shRNAs against Sumo2 or Firefly luciferase
with doxycycline in the presence or absence of ascorbic
acid (AA) (Esteban et al., 2010), a DOT1L inhibitor
(DOT1Li) (Onder et al., 2012), and a GSK3 inhibitor
(GSK3i) (Silva et al., 2008). Consistent with previous re-
ports, we found that exposure of reprogrammable cells to
each of these compounds significantly enhanced the gen-
eration of AP+ iPSC colonies, with combined AA/GSK3i
treatment (AGi) exhibiting the strongest effect (Bar-Nur
et al., 2014). Strikingly, SUMO2 depletion alone even sur-
passed the effect of AGi exposure based on AP+ colony
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Figure 3. Effect of SUMO2 Suppression on
Defined Reprogramming Intermediates
(A) Overview of surface markers and reporter
alleles to distinguish between early, mid, and
late stages of reprogramming.
(B) Flow cytometry analysis of these markers at
intermediate stages of reprogramming in the
presence of indicated shRNAs (tRFP+ cells).
(C) Quantification of data shown in (B) and
Figure S4 using three biological replicates ±
SD; SSEA1 shFirefly sample contains only two
biological replicates; see also Figure S4.
(D) AP+ transgene-independent iPSC colonies
obtained after transfection of reprogrammable
MEFs with indicated siRNAs either once (day 0)
or twice (day 0 and day 3) in the presence of
dox for 6 days; iPSC colonies were scored after
4 days of dox withdrawal to capture stable
iPSCs.
(E) Quantification of data shown in (D) using
three biological replicates (mean ± SD).
(F) Correlation analysis between microarray
data obtained in this study (day-6 reprogram-
ming cultures expressing either Firefly or
Sumo2 shRNAs, single data points) and a pre-
viously reported reprogramming time course
(Polo et al., 2012).
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numbers (Figure 4E). Moreover, suppression of SUMO2
further enhanced iPSC formation in the presence of either
ascorbate, GSK3i, or DOT1Li (Figure 4F). These results un-
derscore the strong effects of SUMO2 suppression alone
on the reprogramming process and suggest that the sumoy-
lation pathway may act in parallel to previously described
facilitators of iPSC formation, including AA and inhibitors
of H3K79 methylation and GSK3/WNT signaling.
Generation of iPSCs after as Little As 38Hours ofOKSM
Expression
Given the additive effect between SUMO2 suppression and
small molecule enhancers of reprogramming, we asked
whether this combination treatment would allow us to
further reduce theminimal timeperiodofOKSMexpression
required to produce stable transgene-independent iPSCs.
We used early passage reprogrammable MEFs (passage 2)
carrying two copies of each of the Col1a1-tetOP-OKSM and
R26-M2rtTA alleles to achieve optimal reprogramming effi-
ciencies (Stadtfeld et al., 2010). MEFs exposed to DOT1Li,
GSK3i, and AA required only 72 hr of OKSM expression to
produce thefirst dox-independentAP+ iPSCs,which is faster
than any previously reported protocol (Figures 5A and 5B).
Remarkably, suppression of SUMO2 further reduced this
time window to 38 hrs. Emerging iPSC colonies activated
the endogenous Oct4-GFP reporter, expressed endogenous
NANOG, OCT4, and SOX2, gave rise to well-differentiated
teratomas, and supported the formation of coat-color chi-
meras, indicating acquisition of an authentic iPSC state
(Figures 5C–5F). Analysis of global transcriptional patterns
of these iPSCs further revealed a remarkable similarity
with either iPSCs generated after 10 days of OKSM expres-
sion or with an established ESC line, suggesting that abbre-
viated OKSM expression in the presence of chemicals and
Sumo2 siRNAs does not compromise the pluripotency
program (Figures 5G–5I and S5). These results show that
1–2 days of OKSM expression are sufficient to produce
stable, pluripotent iPSCs when SUMO2 expression is tran-
siently suppressed under optimal culture conditions.
Finally, we tested whether suppression of SUMO2 also
enhances human reprogramming. To this end, we infected
human dermal fibroblasts with vectors expressing OKSM
and either SUMO2 or FIREFLY (FF) shRNAs and measured
the formation of AP+ colonies at day 21 (Figures 5J–5L).
Consistent with our observations in the mouse system,
we find that suppression of SUMO2 increases the
formation of human iPSC-like colonies by 4- to 6-fold.
We also noticed that human iPSC-like colonies expressing
SUMO2 shRNAs formed earlier than controls, suggesting
acceleration of reprogramming (data not shown). Thus, su-
moylation is a conserved reprogramming barrier across
murine and human somatic cells.
DISCUSSION
Here, we identified SUMO2 as a potent roadblock to
iPSC generation by combining a well-defined transgenic
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Figure 4. SUMO2 Suppression Acts Independently of C-MYC and
in Parallel with Small Molecules
(A) Scheme depicting reprogrammable MEFs carrying Col1a1-tetOP-
OKS-mCherry and Rosa26-M2rtTA alleles. Black triangles depict
M2rtTA protein; green, purple, and blue ovals show OCT4, SOX2, and
KLF4 proteins; red star symbolizes mCHERRY protein.
(B) Generation of AP+ transgene-independent iPSC colonies ob-
tained from these reprogrammable MEFs transfected with indicated
shRNAs after exposure to dox and small molecules for 9 days.
(C) Quantification of data shown in (B), ‘‘dox only’’ samples and
additional time points; data show mean from three biological
replicates ± SD.
(D) Oct4-GFP expression of OKS reprogrammable MEFs treated with
indicated siRNAs and dox for 9 days, followed by 5 days of dox-
independent growth.
(E) Comparison of iPSC formation efficiencies from OKSM re-
programmable MEFs in the presence of either small molecules or
siRNAs targeting Sumo2. Values show mean from three biological
replicates ± SD.
(F) Combination treatment of reprogrammable MEFs with siRNA
targeting Sumo2 and indicated small molecule. Values show mean
from three biological replicates ± SD.
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Figure 5. Generation of iPSCs after as Little as 38 Hours of OKSM Expression and Human Reprogramming Experiments
(A) Treatment with ascorbic acid (AA), DOT1L inhibitor (DOT1Li), and GSK3 inhibitor (GSK3i) facilitates the recovery of transgene-
independent AP+ iPSC colonies from control and Sumo2 siRNA transfected MEFs after 72 hr of OKSM expression.
(B) Quantification of data shown in (A) using three biological replicates (mean ± SD).
(C) Suppression of SUMO2 enables generation of Oct4-GFP+ transgene-independent iPSCs after 38 hr of OKSM expression in the presence of
the indicated small molecules.
(D) Representative immunofluorescence images showing expression of endogenous OCT4, NANOG, and SOX2 in iPSCs generated after 38 hr
of OKSM expression and Sumo2 siRNA transfection.
(E) iPSCs shown in (C) are pluripotent as determined by their potential to differentiate into the three germ layers in teratomas.
(F) iPSCs produced after 38 hr of OKSM expression give rise to coat-color chimeras.
(G–I) Correlation analysis of microarray data (single data points) between MEFs and iPSCs derived after 38 hr of OKSM expression and
Sumo2 siRNA transfection (38hr iPSCs) (G), 38hr iPSCs and ESCs (H), and iPSCs derived after 10 days of OKSM and Sumo2 shRNA expression
(10 day iPSCs) and ESCs (I).
(J) Suppression of SUMO2mRNA levels in foreskin fibroblasts using SUMO2 or FIREFLY shRNA vectors as determined by qPCR. RNA from three
independent experiments was pooled for qPCR analysis; values represent means from three technical replicates ± SD.
(legend continued on next page)
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reprogramming system with a genome-wide shRNA
screening approach. In contrast to previous shRNA or
siRNA screens conducted during iPSC formation, we em-
ployed a serial shRNA enrichment strategy, which may
reduce the number of false-positive hits and allow for selec-
tion of shRNAs with stronger phenotypes. Indeed, suppres-
sion of a top candidate, SUMO2, markedly enhanced and
accelerated iPSC formation compared with individual hits
that emerged from previous large-scale screens or candi-
dates that were selected based on gene-expression differ-
ences between somatic and pluripotent cells. In agreement
with the notion that the expression of barrier genes does
not necessarily have to be different between MEFs and
iPSCs, we found that Sumo2 mRNA levels do not dramati-
cally change during reprogramming. To our knowledge,
iPSC formation after 38 hr of OKSM expression represents
the shortest time period that has been reported to obtain
stably reprogrammed cells from fibroblasts. In addition to
SUMO2, our screen uncovered a number of other candidate
barriers to iPSC formation, which provide a useful resource
for future mechanistic studies of the reprogramming
process.
While SUMO2 has not previously been recognized as a
roadblock to reprogramming, a recent report suggested
that knockdown of the upstream SUMO-conjugating
enzyme UBC9 blocks iPSC formation (Tahmasebi et al.,
2014). Several reasons may account for the apparent
discrepancy between our studies. For example, UBC9
knockdown is expected to inhibit SUMO1, SUMO2, and
SUMO3, which may be toxic to cells, whereas SUMO2
depletionmay be tolerated by cells owing to compensation
by SUMO1 and/or SUMO3. In support of this idea, Ubc9
deletion in vivo causes a more severe phenotype compared
with individual deletion of Sumo1, Sumo2, or Sumo3
(Wang et al., 2014). Furthermore, knockdown of UBC9 in
ESCs reportedly triggers differentiation (Tahmasebi et al.,
2014). Considering that the same constitutive knockdown
vectors were used to assess UBC9’s role in ESC self-renewal
and reprogramming, it is possible that a potential increase
in the number of iPSCs was overlooked due to their imme-
diate loss through differentiation. Indeed, a recent shRNA
screen conducted during iPSC formation with retroviral
vectors, which become silenced in iPSCs, identified UBC9
as a potent reprogramming barrier (Cheloufi et al., 2015).
Mechanistically, SUMO2depletionmayenhance iPSCfor-
mationbyderepressingepigenetically silencedpluripotency
loci (Poleshkoetal., 2014;Yangetal., 2015) aswell ashistone
and protein biosynthesis genes important for cellular
growth and proliferation (Neyret-Kahn et al., 2013). Consis-
tently, we find that key pluripotency genes and epigenetic
regulators are expressed more robustly in SUMO2-depleted
reprogramming intermediates compared with controls. In
addition, SUMO2 suppression may contribute to iPSC for-
mation by directly modulating certain pluripotency factors
during iPSC generation. In agreement with this view, su-
moylation of SOX2 and KLF4 reportedly impairs transcrip-
tional activity and compromises pluripotency (Tahmasebi
et al., 2013;Wuet al., 2012).Moreover, overexpressionof su-
moylation-deficient variants of these transcription factors
slightly enhances reprogramming into iPSCs, although the
reported effects were subtle compared with the phenotype
reported here. Considering these observations and our pre-
liminary finding that KLF4 is not differentially sumoylated
upon suppression of SUMO2, we surmise that SUMO2
acts at multiple levels to resist the acquisition of pluripo-
tency rather than to control the activity or stability of a
single protein target. It should be informative to identify
relevant SUMO2 targets in MEFs and iPSCs using recently
developedproteomics andchromatin immunoprecipitation
sequencing (Becker et al., 2013; Neyret-Kahn et al., 2013)
approaches.
Our findings may have practical implications for basic
science and cell therapy. The ease with which SUMO2
can be inhibited using transient siRNA delivery should
facilitate the mechanistic dissection of the reprogramming
process in more homogeneous cell cultures. The observa-
tion that SUMO2 depletion increases human iPSC genera-
tion, cooperates with small-molecule enhancers of reprog-
ramming, and negates the need for exogenous C-MYC
expression, may further facilitate the efficient and safe gen-
eration of patient-specific iPSCs from rare donor cells.
EXPERIMENTAL PROCEDURES
Tissue Culture and Virus Production
Reprogrammable mouse embryonic fibroblasts (RepMEFs) were
derived from embryonic day 13.5–15.5 embryos carrying either
the Col1a1-tetOP-OKSM or Col1a1-tetOP-OKS-mCherry alleles in
combination with the Rosa26-M2rtTA alleles (Bar-Nur et al.,
2014; Stadtfeld et al., 2010). Reprogramming was initiated by add-
ing 20 ng/ml doxycycline (dox) (Sigma, catalog #D9891-25G) to
RepMEFs and, where indicated, 25 mg/ml L-AA (Sigma, catalog
#A4544-25G), 3 mM GSK3 inhibitor (CHIR99021, Stemgent, cata-
log #04-0004), ALK5 inhibitor (Calbiochem, catalog #616452),
(K) Reprogramming efficiency of cells characterized in (J) as measured by the number of AP+ colonies per 60,000 plated fibroblasts. Values
represent means from three biological replicates ± SD.
(L) Representative images of bright-field and AP+ colonies obtained with SUMO2 and FIREFLY shRNA vectors after 14 and 21 days of OKSM
expression.
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1 mMMEK inhibitor (PD0325901, Stemgent, catalog #04–0006), or
DOT1L inhibitor (generous gift from Dr. Peter Brown). Viral trans-
ductions, using pHage or pGIPZ vectors in combinationwith pack-
agingplasmids psPax2 andpDM2.G,were performed by spin infec-
tion for 30 min at 2,150 rpm at room temperature. The following
shRNA seed sequences were used for mouse experiments: pHage
shRNA (shSumo2 #1), ATAAGAGCTGAATGAGCATGCC; pGIPZ
(shSumo2 #2–7; Dharmacon); #2 (V2LMM_2701), TTCTGGAG
TAAAGTAGCAG; #3 (V2LMM_5114), TAAGAGCTGAATGAG
CATG; #4 (V3LMM_496391), TAGTAGACACCTCCAGTCT; #5
(V3LMM_496392), AAACTGCACCACAGAACCA; #6 (V3LMM_
496393), TGTTCTCAGTCTTGACTCC; #7 (V3LMM_496396),
AATCTTAAACTGCACCACA. Transfections of RepMEFs with
1.5 ml siRNAs (esiRNA technology, Sigma; Sumo2: EMU095391,
Renilla: EHURLUC) were performed in 12-well plates using Lipo-
fectamine 2000 and Opti-MEM (Life Technologies) according
to the manufacturer’s instructions. For human reprogramming
experiments, BJ fibroblasts were first infected with control or
SUMO2 pGIPZ shRNA (V3LHS_388696 and V3LHS412780; GE
Dharmacon) viruses. Two days later, cells were infected with
the human pHAGE-STEMCCA virus (Sommer et al., 2012) to
initiate reprogramming. Cells were replated in fibroblast medium
(DMEM and 10% FBS) and cultured for 4 days. Medium was then
switched to a 1:1 mixture of fibroblast medium and human ESC
medium (E8; STEMCELL Technologies) for another 2 days, and
finally to 100% human ESC medium. Cells were stained for alka-
line phosphatase activity (Stemgent), and AP+ iPSCs were counted
3 weeks after STEMCCA infection.
Flow Cytometry
For isolation of Oct4-GFP+ iPSCs, SSEA1+ cells were first enriched
by MACS sorting using SSEA1 antibody-coated magnetic beads
(Miltenyi). Oct4-GFP+ cells were then purified within the enriched
SSEA1+ fraction by FACS. Gates were set based on uninfectedMEFs,
virally transduced MEFs (tRFP+), and Oct4-GFP+ iPSCs. Intermedi-
ates of reprogramming were analyzed by flow cytometry using the
following antibodies: THY1-Viogreen (Becton Dickinson, catalog
#561616) or THY1-Pacific Blue (eBioscience, catalog #48-0902-
82), SSEA1-APC (Biolegend, catalog #125608) or SSEA1-PE-Cy7
(Miltenyi Biotec, catalog #130-100-426), and EPCAM-PE-Cy7
(eBioscience, catalog #25-5791-80) (1:200 for 30 min at 4C).
BD’s Annexin V kit was used to measure apoptotic cells. All cytom-
etry data were analyzed and plotted using FlowJo software.
Quantification of Reprogramming Efficiencies
Formacroscopic detection of iPSC colonies, AP stainingwas carried
out according to manufacturer’s instructions using the Vector
Labs AP staining kit (catalog #5100). AP staining was always per-
formed 2–4 days after doxwithdrawal to eliminate partially reprog-
rammed colonies and to score for transgene-independent iPSCs.
Colonies were counted manually or by custom-made Nikon soft-
ware (CL-Quant).
Teratoma and Chimera Formation
For teratoma generation, iPSC lines (passage 6 or higher) were har-
vested and resuspended in 600 ml medium per confluent six wells.
Mice were anesthetized with Avertin and injected with 150 ml cell
suspension subcutaneously. Tumors were harvested 3–4 weeks af-
ter injection and analyzed histologically. For chimera production,
iPSC lines were injected as a single-cell suspension into day-3.5
blastocysts isolated from intercrosses of C57Bl/63BDF1mice. Blas-
tocysts were transferred into pseudopregnant Swiss Webster recip-
ient animals.
Immunofluorescence Analysis
iPSC lines (passage 6 or higher) were seeded in a 24-well plates at
a low density. Once small colonies emerged, wells were washed
with 13 PBS and fixed by a 5- to 10-min incubation in 10%
formalin at room temperature. After washes in 13 PBS, cells were
blocked in 13 PBS containing 2% BSA and 0.1% Triton X-100.
Primary and secondary antibodies were diluted in blocking solu-
tion at a concentration of 1:200 and added for 1 hr at room temper-
ature or overnight at 4C. Primary antibodies were anti-NANOG
(Abcam, catalog #AB80892), anti-SOX2 (Santa Cruz Biotech-
nology, catalog #Sc-17320), anti-OCT4 (Santa Cruz, catalog #Sc-
8628); secondary antibodies were donkey anti-goat immunoglob-
ulin G (IgG) or donkey anti-rabbit IgG Alexa Fluor 546-conjugated
antibodies (Life Technologies). After two washes in 13 PBS, cells
were immobilized on slides in mounting medium containing
DAPI (Vectashield, Vector Labs) and analyzed.
RNA Expression Analysis
For global gene-expression analysis, total RNA was isolated from
indicated samples using an RNeasyMini Kit (Qiagen) and analyzed
by Affymetrix microarray chips. The raw microarray expression
signals in the CEL files were normalized using the Affymetrix
Expression Console software and robust multiarray averaging
normalization. For qPCR analysis, Brilliant III SYBR-Green-based
master mix was used according to the manual (Agilent), following
RNA isolation (RNeasy kit, Qiagen) and reverse transcription (Tran-
scriptor First Strand cDNA Synthesis Kit, Roche) of Sumo2 or con-
trol knockdown samples 2 days after initiation of reprogramming.
Samples were run in triplicate on the Lightcycler 480 (Roche).
Primer sequences for qPCR were as follows: Sumo2 (forward), AAG
GAAGGAGTCAAGACTGAGAA; Sumo2 (reverse), CGGAATCT
GATCTGCCTCATTG; GAPDH (forward), AGGTCGGTGTGAACG
GATTTG; GAPDH (reverse), TGTAGACCATGTAGTTGAGGTCA.
Scatterplot
Microarray gene-expressionmeasurements for samples containing
Sumo2 or Firefly shRNA for 6 days were obtained. For genes with
more than one probe, the average of all probes was used. These
expression measurements were plotted (on a log2 scale), with
Firefly expression on the x axis, Sumo2 knockdown expression
on the y axis, and each point representing a gene. Genes falling
outside of the dashed lines have a fold change of greater than 1.5
between Sumo2 knockdown and Firefly. Some key genes were
highlighted, with those being upregulated in Sumo2 knockdown
colored red, and those downregulated colored green.
Correlation Matrix
Previously published microarray gene-expression measurements
representing stages of reprogramming were obtained from GEO
(GSE42379). The following samples were used: KH2-MEF_m2,
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KH2-MEF_m3, Day3_SSEA1+ M2, Day3_SSEA1+ M3, Day6_
SSEA1+ M2 and Day6_SSEA1+ M3, Day9_SSEA1+ M2, Day12_
SSEA1+ M2, iPS_KH2-SC_MEF_1–5, iPS_KH2-SC_MEF_1–6, and
iPS_KH2-SC_MEF_1–3 (GSM1038591, GSM1038592, GSM103
8595, GSM1038598, GSM1038601, GSM1038604, GSM1038607,
GSM1038611, GSM1038612, GSM1038613, GSM1038614), repre-
senting day 0 of reprogramming (MEF), day 3, day 6, day 9, day 12,
and fully reprogrammed (iPS). For time points with multiple sam-
ples, the average expressionmeasurement for each probewas used.
For genes with more than one probe, the average of all probes was
used.
The gene-expression measurements of the Sumo2 knockdown
and Firefly samples were compared with those of the samples rep-
resenting stages of reprogramming. Only the genes that were pre-
sent in both datasets were considered. To remove the batch effect
we used the ‘‘Remove Batch Effect’’ tool in the Partek Genomics
Suite, which fits a linear model to the data which includes batch
as a component, then subtracts that component from the data.
A matrix was constructed with pairwise comparisons between
the Sumo2 knockdown and Firefly samples (as the rows in the
matrix) and each of the samples representing stages of reprogram-
ming (as the columns in the matrix). A scatterplot was generated
and a Pearson’s R correlation coefficient was calculated for each
pairwise comparison. Scatterplots that are shaped closer to a
straight line and have a higher correlation coefficient indicate
that the global expression patterns of the two samplesmore closely
match.
Western Blot Analysis
Protein lysates were run on 4%–20% Mini Protean TGX gels (Bio-
Rad), blotted onto Immobilon-P membrane (EMD Millipore),
and incubated with anti-SUMO2 antibody ab3742 (Abcam) and
anti-RAN antibody 610341 (BD) for western blot analysis. We
used anti-KLF4 antibody AF3158 (R&D Systems), anti-OCT4 anti-
body 11,263-1-AP (ProteinTech), and anti-SUMO2 antibody
ab81371 (Abcam) for immunoprecipitation experiments.
Generation of pHAGE-Mir Vector
The pHAGE lentiviral backbone was released from pHAGE-EF1a-
eGFP-W vector (kindly provided by Dr. Richard Mulligan’s labora-
tory) using NotI + BamHI. tRFP was PCR amplified from
pTurboRFP-N (Evrogen) and blunt-end cloned into the above
pHAGE backbone to generate the intermediate pHAGE-EF1a-tRFP
vector. The Mir30-shRNA cassette and PGK-Puro selection marker
was digested from MSCV-PM using BgIII + ClaI, and blunt-end
cloned into the BamHI digested pHAGE-EF1a-tRFP intermediate
to generate the pHAGE-Mir vector.
shRNA Screen and Identification of Hits
RepMEFswere expanded until passage 4 in 4%oxygen, switched to
atmospheric oxygen, and infected with the pooled shRNA library
as described above. For each shRNA (621,000 shRNAs in total),
1–2 3 103 cells were infected to achieve good coverage. Infected
cells were passaged onto gelatinized 15-cm cell culture dishes (Fal-
con) in reprogrammingmedium (ESCmedium supplementedwith
AA and dox) for 10 days, and in dox/ascorbic acid-free ESC media
for an additional 4 days. Cells were harvested, pooled, and purified
with SSEA1-linkedmagnetic beads using anAutoMACS sorter (Mil-
tenyi). SSEA1-enriched cells were then FACS sorted for endogenous
Oct4-GFP expression.
Genomic DNA was extracted from collected Oct4-GFP+ cells by
lysing the cells in 10 mM Tris (pH 8.0), 10 mM EDTA, 10 mM
NaCl, and 0.5% sarkosyl. Lysates were treated with 0.1 mg/ml
RNase A at 37C for 30 min and 0.5 mg/ml proteinase K at 55C
for 1–2 hr, then phenol-chloroform extracted, ethanol precipi-
tated, and resuspended in 10 mM Tris-HCl (pH 8.0). For each sam-
ple, all the genomicDNAwas used as template for shRNAPCR, usu-
ally in multiple PCR reactions. Each 50 ml PCR reaction contained
2.5 mg genomic DNA template, 200 mM dinucleotide triphos-
phates (dNTPs), 400 nM of each PCR primer (pHAGE-Mir-PCR,
50-GCAAACTGGGGCACAGATGATGCGG; BC1R-L, 50-CGCCTCC
CCTACCCGGTAGA), 13 Q5 reaction buffer, 13 Q5 high GC
buffer, and 0.5 ml Q5 polymerase (NEB). PCR was performed with
the following program: 94C for 4 min, 35 cycles of (94C 30 s,
60C 30 s, 72C 45 s), and 72C for 10 min. PCR products
(700 bp) for each sample were pooled, ethanol precipitated, re-
suspended, and gel purified using the QIAquick Gel Extraction
Kit (Qiagen). The purified shRNA PCR products were used to (1)
generate sublibraries for the next round of shRNA library screens
and (2) generate sequencing libraries for Illumina sequencing.
For sublibrary generation, the purified PCR product was digested
with NotI and MluI, and the 400 -bp fragment that contains the
shRNAs was gel purified. Separately, the pHAGE-Mir plasmid was
also digested with NotI andMluI to recover the9 kb vector back-
bone. The purified shRNA fragment (25–50 ng) and the vector
backbone (125–250 ng) were ligated in a 5 ml ligation reaction
using NEB T4 ligase. A 1 ml ligation reaction was used to transform
20 ml Electromax competent cells DH10b (Life Technologies) with
electroporation. Onemicroliter of the transformation reactionwas
plated on one 10 cm LB-Amp (100 mg/ml) plate to estimate the to-
tal number of colonies, and the rest of the transformation reaction
was plated on two 15 cm LB-carbenicillin (100 mg/ml) plates and
grown overnight at 37C. At least 1003 coverage was needed to
maintain the representation of the library (i.e., colony number =
100 3 the number of shRNAs in the library). When necessary,
the entire ligation reactionmay be used for transformation inmul-
tiple electroporation reactions to increase the number of colonies.
The next day, lawns formed on the two 15 cm plates were scraped
off and cultured in 300 ml LB-carbenicillin (100 mg/ml) medium
and grown at 30C for 2–3 hr. The bacteria were collected and
the cloned sublibrary DNA was extracted by the Genelute Maxi-
prep kit (Sigma).
For Illumina sequencing, the purified shRNA PCR product was
used as template for another round of PCR: 500 ng purified shRNA
PCRproduct, 200mMdNTPs, 2mMeachPCRprimer (p5andp7), 13
Q5 reaction buffer, 13Q5 high GC buffer, and 1 ml Q5 polymerase
(NEB) in 100 ml PCR reaction buffer. PCR was performed with the
following program: 94C for 4 min, two cycles of (94C 30 s,
50C 20 s, 72C 30 s), 20 cycles of (94C 30 s, 60C 20 s, 72C
30 s), and 72C for 10 min. PCR products (120 bp) were gel puri-
fied using the QIAquick Gel Extraction Kit (Qiagen). Gel-purified
products were submitted for Illumina sequencing on the Illumina
MiSeq instrument, using a custom sequencing primer: mir30-
EcoRI: 50-TAGCCCCTTGAATTCCGAGGCAGTAGGCA.
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PCR primers: p5-miSeq, 50-ATGATACGGCGACCACCGAGATC
TACACCTAAAGTAGCCCCTTGAATTC; p7-miSeq-1, 50-CAAGCA
GAAGACGGCATACGAGACGATAGTGAAGCCACAGATGTA; p7-
miSeq-2, 50-CAAGCAGAAGACGGCATACGAGACACTAGTGAAG
CCACAGATGTA; p7-miSeq-3, 50-CAAGCAGAAGACGGCATAC
GAGACTATAGTGAAGCCACAGATGTA; and p7-miSeq-4, 50-CAA
GCAGAAGACGGCATACGAGACCTTAGTGAAGCCACAGATGTA.
Different p7 primers were used for multiplexing purposes.
Single-end 51-bp reads were obtained using the Illumina HiSeq
or MiSeq instrument. The reads are expected to have an initial 22
nucleotides that identify the shRNA, followed by a constant region
that is the same for all shRNAs and a two-nucleotide barcode to
identify the sample. Reads that contain perfect matches at the
following six nucleotides were first extracted from the sequencing
data: the two nucleotides adjacent to the initial 22 base sequence
and the two nucleotides adjacent to the barcode on both sides.
The shRNAs were then identified by requiring an exact match of
the 22 nucleotides to the sequences in the shRNA library annota-
tion file. The samples were identified by the two-nucleotide
barcodes.
The total number of reads that were identified for each shRNA,
sample, and round were counted. The counts were normalized to
be directly comparable between samples and rounds by first
dividing by the total number of counts for that sample and round,
and then multiplying by the total number of shRNAs in the initial
library. A pseudocount of 1 was added to each normalized count to
downweight enrichment derived from low-read counts and to
avoid division by zero in calculating fold changes.
The enrichment for each shRNA in each round was calculated as
the log2 fold change of the Oct4-GFP+ normalized counts over the
maximum of the normalized counts of the controls (T0, No-Dox,
and Oct4-GFP cells). The cumulative enrichment for each shRNA
in each round was calculated as the sum of the log2 fold changes
for that round and all previous rounds. The overall enrichment
of each shRNA was defined as the maximum of the cumulative
enrichment scores among all rounds.
The heatmap for Figure 1G was plotted using the cumulative
enrichment scores. Only shRNAs that have at least one read in
the Oct4-GFP+ sample in at least two rounds were used in the
plot, resulting in a total of 23,853 shRNAs.
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